Scholarlink

Background <p>Brain metastases (BM) are among the most common intracranial tumors. Despite advances in multimodal therapy for newly diagnosed BM, the management of recurrent BM remains a clinical challenge. Due to the lack of robust data, there is currently no consensus regarding optimal salvage treatment for recurrent BM.</p> Methods <p>Institutional data (2016–2025) and published data from the literature (2011–2025) were analyzed with respect to overall survival (OS) and progression-free survival (PFS) after recurrence. Survival data were extracted from Kaplan-Meier curves of the selected studies using the R package IPDfromKM and pooled survival analyses were performed.</p> Results <p>In a pooled analysis of 776 patients, local surgical re-resection after recurrence was associated with significantly longer survival compared to both non-surgical management (median 14.74 [95% CI: 11.68–17.80] vs. 10.34 months [95% CI: 8.59–12.08]; HR: 0.664; <i>p</i> &lt; 0.001) and only repeat stereotactic radiosurgery (Re-SRS) (median 14.74 months [95% CI: 10.51–18.98] vs. 10.97 months [95% CI: 9.1–12.84]; HR: 0.62; <i>p</i> &lt; 0.001). Among patients who underwent local re-resection, gross total resection (GTR) led to markedly improved OS compared to subtotal or incomplete resection (median 23.97 months [95% CI: 15.95–31.99] vs. 7.06 months [95% CI: 5.21–8.90]; HR: 0.400; <i>p</i> &lt; 0.0001). The addition of adjuvant re-radiotherapy after re-resection did not result in a significant survival benefit (<i>p</i> = 0.357). Regarding PFS, patients treated with local re-resection alone had the longest median PFS (43.23 months), significantly outperforming both those receiving re-resection plus adjuvant re-SRS (29.92 months; HR = 0.529; <i>p</i> &lt; 0.001) and those treated with Re-SRS alone (15.79 months; HR = 3.031; <i>p</i> &lt; 0.001).</p> Conclusions <p>This study highlights the role of local re-resection in improving survival among patients with recurrent brain metastases amenable to repeat GTR. Re-SRS remains a valuable salvage option, particularly for patients in whom GTR is not feasible. While adjuvant re-radiotherapy following re-resection did not demonstrate a clear survival advantage in our analysis, it may offer additional local control in selected cases. These findings emphasize the importance of individualized, multidisciplinary decision-making to tailor salvage strategies to patient- and tumor-specific factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment modalities in recurrent brain metastases: a combined institutional and individual patient data meta-analysis of post-recurrence survival and local progression-free survival

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Alim Emre Basaran,
  • Luca Fahsold,
  • Florian Lordick,
  • Nils H. Nicolay,
  • Erdem Güresir,
  • Johannes Wach

摘要

Background

Brain metastases (BM) are among the most common intracranial tumors. Despite advances in multimodal therapy for newly diagnosed BM, the management of recurrent BM remains a clinical challenge. Due to the lack of robust data, there is currently no consensus regarding optimal salvage treatment for recurrent BM.

Methods

Institutional data (2016–2025) and published data from the literature (2011–2025) were analyzed with respect to overall survival (OS) and progression-free survival (PFS) after recurrence. Survival data were extracted from Kaplan-Meier curves of the selected studies using the R package IPDfromKM and pooled survival analyses were performed.

Results

In a pooled analysis of 776 patients, local surgical re-resection after recurrence was associated with significantly longer survival compared to both non-surgical management (median 14.74 [95% CI: 11.68–17.80] vs. 10.34 months [95% CI: 8.59–12.08]; HR: 0.664; p < 0.001) and only repeat stereotactic radiosurgery (Re-SRS) (median 14.74 months [95% CI: 10.51–18.98] vs. 10.97 months [95% CI: 9.1–12.84]; HR: 0.62; p < 0.001). Among patients who underwent local re-resection, gross total resection (GTR) led to markedly improved OS compared to subtotal or incomplete resection (median 23.97 months [95% CI: 15.95–31.99] vs. 7.06 months [95% CI: 5.21–8.90]; HR: 0.400; p < 0.0001). The addition of adjuvant re-radiotherapy after re-resection did not result in a significant survival benefit (p = 0.357). Regarding PFS, patients treated with local re-resection alone had the longest median PFS (43.23 months), significantly outperforming both those receiving re-resection plus adjuvant re-SRS (29.92 months; HR = 0.529; p < 0.001) and those treated with Re-SRS alone (15.79 months; HR = 3.031; p < 0.001).

Conclusions

This study highlights the role of local re-resection in improving survival among patients with recurrent brain metastases amenable to repeat GTR. Re-SRS remains a valuable salvage option, particularly for patients in whom GTR is not feasible. While adjuvant re-radiotherapy following re-resection did not demonstrate a clear survival advantage in our analysis, it may offer additional local control in selected cases. These findings emphasize the importance of individualized, multidisciplinary decision-making to tailor salvage strategies to patient- and tumor-specific factors.